ZÜRICH, Switzerland, April 23, 2024 (GLOBE NEWSWIRE) -- CDR-Life Inc.
(https://www.cdr-life.com/) today announced a presentation on its proprietary
antibody-major histocompatibility complex (MHC) technology for the development
of highly specific T-cell engagers (TCE) at the TCR-Based Therapies for Solid
Tumors Summit, occurring April 23-25 in Boston, Massachusetts.
The presentation will discuss how antibodies targeting tumor peptides on the MHC
enable T-cells access to an untapped reservoir of intracellular tumor antigens
and will highlight the M-gager(®) technology's ability to leverage the potency,
versatility and manufacturability of antibodies to revolutionize cancer
immunotherapy.
Presentation Details
Title: Unlocking Tumor Eradication with Antibody-MHC T Cell Engagers
Presenter: Leonardo Borras, Chief Scientific Officer
Date: April 23, 2024
About CDR-Life
CDR-Life is developing powerful T-cell engagers (TCE) to eradicate hard-to-treat
solid tumors. Our integrated antibody-based TCE platform unlocks access to a
wide range of cancer antigens. We are leveraging this platform to advance a
pipeline of potent and selective TCE therapeutics targeting intracellular and
surface tumor antigens. With a team of proven drug development experts and
backed by leading cross-Atlantic investors, we are working to empower patients'
own immune systems to eliminate tumors.
Â